University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Addiction. 2012 Jan;107(1):131-41. doi: 10.1111/j.1360-0443.2011.03552.x. Epub 2011 Oct 10.
Whether the selective serotonin re-uptake inhibitor sertraline at 200 mg/day delays relapse in recently abstinent cocaine-dependent individuals.
The study involved a 12-week, double-blind, placebo-controlled clinical trial with 2-week residential stay followed by 10-week out-patient participation.
Veterans Affairs residential unit and out-patient treatment research program.
Cocaine-dependent volunteers (n = 86) with depressive symptoms (Hamilton score > 15), but otherwise no major psychiatric or medical disorder or contraindication to sertraline.
Participants were housed on a drug-free residential unit (weeks 1-2) and randomized to receive sertraline or placebo. Participants then participated on an out-patient basis during weeks 3-12 while continuing to receive study medication. Patients participated in a day substance abuse/day treatment program during weeks 1-3 and underwent weekly cognitive behavioral therapy during weeks 4-12. The primary outcome measure was thrice-weekly urine results and the secondary measure was Hamilton Depression scores.
Pre-hoc analyses were performed on those who participated beyond week 2. Generally, no group differences in retention or baseline characteristics occurred. Sertraline patients showed a trend towards longer time before their first cocaine-positive urine ('lapse', χ(2) = 3.67, P = 0.056), went significantly longer before having two consecutive urine samples positive for cocaine ('relapse', χ(2) = 4.03, P = 0.04) and showed significantly more days to lapse (26.1 ± 16.7 versus 13.2 ± 10.5; Z = 2.89, P = 0.004) and relapse (21.3 ± 10.8 versus 32.3 ± 14.9; Z = 2.25, P = 0.02). Depression scores decreased over time (F = 43.43, P < 0.0001), but did not differ between groups (F = 0.09, P = 0.77).
Sertraline delays time to relapse relative to placebo in cocaine-dependent patients who initially achieve at least 2 weeks of abstinence.
观察每日 200 毫克选择性 5-羟色胺再摄取抑制剂舍曲林是否能延缓近期戒断可卡因的个体复发。
这是一项为期 12 周的双盲、安慰剂对照临床试验,包括 2 周住院期和 10 周门诊随访。
退伍军人事务部住院部和门诊治疗研究计划。
有抑郁症状(汉密尔顿评分>15)但无其他重大精神或医学障碍或舍曲林禁忌证的可卡因依赖志愿者(n=86)。
参与者入住无毒品的住院病房(第 1-2 周),并随机分为舍曲林组或安慰剂组。然后,参与者在第 3-12 周继续接受研究药物,同时进行门诊治疗。患者在第 1-3 周参加每日物质滥用/每日治疗计划,并在第 4-12 周每周接受认知行为疗法。主要结局指标为每周三次的尿液检测结果,次要指标为汉密尔顿抑郁评分。
对第 2 周后仍参与研究的患者进行了预先分析。一般来说,保留率或基线特征在两组间无差异。舍曲林组首次可卡因阳性尿液的时间(“复吸”,χ(2) = 3.67,P = 0.056)有延长趋势,连续两次可卡因阳性尿液的时间(“复发”,χ(2) = 4.03,P = 0.04)有显著延长,并且复吸(21.3 ± 10.8 与 32.3 ± 14.9;Z = 2.25,P = 0.02)和复发(26.1 ± 16.7 与 32.3 ± 14.9;Z = 2.89,P = 0.004)的天数也显著增加。抑郁评分随时间下降(F = 43.43,P < 0.0001),但两组间无差异(F = 0.09,P = 0.77)。
舍曲林能延迟近期戒断可卡因的患者复发时间,前提是他们至少能保持 2 周的戒断状态。